India Gets Its First Dengue Vaccine as DCGI Clears QDENGA
New Delhi: Public health in India has been positively impacted by the approval of QDENGA, the first dengue vaccine, by its Drug Controller General of India (DCGI). This is a groundbreaking move. The move is expected to help the country's fight against dengue, a mosquito-borne disease that affects millions and causes seasonal outbreaks in many states.
Takeda Biopharmaceuticals has created QDENGA, a dengue virus vaccine that targets all four known strains. The vaccine is viewed as a significant breakthrough because it can be administered without the need for prior testing to determine whether an individual has contracted dengue before, simplifying large-scale immunisation initiatives.
The vaccine is now available to individuals aged 4 to 60.. Despite clinical trials indicating its effectiveness in decreasing the risk of severe outbreaks and hospital stays, dengue is still one of the major public health challenges faced by India, especially during monsoon and post-monsophageal mosquito outbreak seasons. The country's significant contribution to dengue outbreaks means that the implementation of an approved vaccine may aid in reducing the burden on medical facilities and improving disease control across the nation.
In numerous countries worldwide, QDENGA has already been authorized and administered to millions.. After a thorough scientific assessment, it has been sanctioned in India and is considered essentially supplementary to strengthening the nation's disease-prevention system.
In order to maintain sufficient supply, Takeda has joined forces with Biological E, an Indian vaccine manufacturer, to increase production capacity. India's collaboration is expected to aid in the fulfillment of domestic demand and global supply of vaccines.
According to health experts, vaccination alone does not guarantee the eradication of dengue. They emphasize the need for ongoing prevention measures, such as removing stagnant water, maintaining cleanliness, using mosquito repellents, and raising awareness of early symptoms and treatment. Health authorities anticipate that the vaccine will aid in minimizing hospital admissions, preventing infections from occurring and protecting vulnerable grou
You might also like!
